---
title: Antipsychotic Drugs
type: content
phase: 1
status: complete
priority: high
tags: [antipsychotics, typical, atypical, schizophrenia, dopamine, FGA, SGA, EPS, metabolic-syndrome]
created: 2025-11-08
last_modified: 2025-11-08
---

# Antipsychotic Drugs

## Introduction

Antipsychotic medications, also called neuroleptics or major tranquilizers, are primarily used to treat psychotic disorders such as schizophrenia, bipolar disorder, and psychotic depression. They are classified into two major categories: typical (first-generation) and atypical (second-generation) antipsychotics. Understanding their mechanisms, efficacy profiles, and adverse effects is crucial for appropriate clinical use.

## Classification

### First-Generation Antipsychotics (FGAs) - Typical Antipsychotics

**High Potency**:
- Haloperidol
- Fluphenazine
- Trifluoperazine
- Pimozide

**Mid Potency**:
- Loxapine
- Perphenazine
- Molindone

**Low Potency**:
- Chlorpromazine
- Thioridazine

### Second-Generation Antipsychotics (SGAs) - Atypical Antipsychotics

- Risperidone
- Olanzapine
- Quetiapine
- Aripiprazole
- Ziprasidone
- Paliperidone
- Asenapine
- Iloperidone
- Lurasidone
- Brexpiprazole
- Cariprazine
- Clozapine (unique - most atypical)

---

## Mechanism of Action

### Typical Antipsychotics

**Primary Mechanism**: D2 dopamine receptor antagonism

**Dopamine Pathways**:

1. **Mesolimbic Pathway** (VTA → nucleus accumbens, limbic system):
   - Overactive in psychosis
   - D2 blockade → ↓positive symptoms (hallucinations, delusions)
   - **Therapeutic target**

2. **Mesocortical Pathway** (VTA → prefrontal cortex):
   - Underactive in schizophrenia
   - D2 blockade → worsens negative symptoms, cognitive deficits
   - **Adverse effect**

3. **Nigrostriatal Pathway** (substantia nigra → striatum):
   - Normal dopamine function for motor control
   - D2 blockade → extrapyramidal symptoms (EPS)
   - **Major adverse effect**

4. **Tuberoinfundibular Pathway** (hypothalamus → pituitary):
   - Dopamine inhibits prolactin
   - D2 blockade → ↑prolactin (hyperprolactinemia)
   - **Adverse effect**

**Potency Correlation**:
- **High potency** (haloperidol): Strong D2 binding → ↑EPS, ↓sedation/anticholinergic effects
- **Low potency** (chlorpromazine): Weaker D2 binding → ↓EPS, ↑sedation/anticholinergic effects

### Atypical Antipsychotics

**Multi-receptor Mechanism**:

1. **D2 Antagonism** (lower affinity than FGAs)
   - Limbic selectivity (less nigrostriatal blockade)
   - Lower EPS risk

2. **5-HT2A Serotonin Antagonism** (defining feature)
   - 5-HT2A blockade in cortex → ↑dopamine release
   - Counteracts mesocortical D2 blockade
   - ↓EPS, improves negative symptoms

3. **Additional Receptors** (varies by agent):
   - H1 (histamine): Sedation, weight gain
   - M1 (muscarinic): Anticholinergic effects
   - α1 (adrenergic): Orthostatic hypotension
   - 5-HT1A, 5-HT2C, etc.

**Aripiprazole** (unique):
- D2 **partial agonist** (not antagonist)
- Stabilizes dopamine (↓when high, ↑when low)
- Lowest EPS, metabolic risk

**Clozapine** (gold standard for refractory):
- Multiple receptor actions
- Low D2 affinity, high 5-HT2A
- D4 > D2 selectivity
- M1, H1, α1 blockade

---

## Typical Antipsychotics

### Haloperidol

**Receptor Profile**: High-potency D2 antagonist (minimal other receptors)

**Pharmacokinetics**:
- Oral, IM, IV, long-acting IM decanoate
- Extensive first-pass metabolism
- Hepatic metabolism (CYP3A4, CYP2D6)
- Half-life: 12-36 hours (oral), 3 weeks (decanoate)
- Active metabolites

**Clinical Uses**:
1. **Acute psychosis, agitation** (IM)
2. **Schizophrenia** (chronic maintenance)
3. **Tourette syndrome** (tics)
4. **Delirium** (especially ICU - IV)
5. **Huntington's disease** (chorea)
6. **Nausea/vomiting** (low doses)
7. **Acute mania**

**Adverse Effects**:

**Extrapyramidal Symptoms (EPS)** - High risk:
1. **Acute dystonia** (hours to days):
   - Muscle spasms, torticollis, oculogyric crisis
   - Risk factors: Young males, high-potency FGAs
   - Treatment: Benztropine, diphenhydramine (IM/IV)

2. **Parkinsonism** (days to weeks):
   - Bradykinesia, rigidity, tremor, shuffling gait
   - Treatment: Reduce dose, benztropine, amantadine

3. **Akathisia** (days to weeks):
   - Motor restlessness, inability to sit still
   - Most distressing to patients
   - Treatment: β-blockers (propranolol), benzodiazepines, reduce dose

4. **Tardive dyskinesia** (months to years):
   - Involuntary choreiform movements (tongue, face, extremities)
   - May be irreversible (50% persist after stopping)
   - Risk: Duration of use, older age, females
   - Prevention: Lowest effective dose, regular AIMS monitoring
   - Treatment: Valbenazine, deutetrabenazine; consider switching to clozapine

**Other Adverse Effects**:
- **Neuroleptic malignant syndrome (NMS)**: Rare, life-threatening
  - Rigidity, hyperthermia, autonomic instability, ↑CK, altered mental status
  - Treatment: Stop drug, supportive care, dantrolene, bromocriptine
- **Hyperprolactinemia**: Gynecomastia, galactorrhea, amenorrhea, sexual dysfunction
- **QTc prolongation**: Risk of torsades de pointes (especially IV haloperidol)
- **Anticholinergic effects**: Minimal (high potency)
- **Sedation**: Minimal
- **Seizure threshold lowering**: Dose-dependent

**Contraindications**:
- Parkinson's disease (worsens symptoms)
- Dementia-related psychosis (↑mortality - Black Box Warning)
- QT prolongation, hypokalemia
- Severe CNS depression

**Drug Interactions**:
- CYP3A4 inducers (rifampin, phenytoin) → ↓levels
- CYP3A4 inhibitors (ketoconazole) → ↑levels
- QT-prolonging drugs → additive risk

### Chlorpromazine

**Receptor Profile**: Low-potency D2, plus H1, M1, α1 antagonism

**Pharmacokinetics**:
- Oral, IM
- Hepatic metabolism
- Half-life: 16-30 hours

**Clinical Uses**:
- Schizophrenia (historical - first antipsychotic, 1950s)
- Severe nausea/vomiting
- Intractable hiccups
- Acute mania

**Adverse Effects**:
- **Sedation**: High (H1 blockade)
- **Anticholinergic effects**: High (dry mouth, constipation, urinary retention, blurred vision)
- **Orthostatic hypotension**: High (α1 blockade)
- **EPS**: Lower than high-potency FGAs
- **Photosensitivity**: Skin reactions
- **Blue-gray skin discoloration**: Chronic use
- **Corneal/lens deposits**
- **Cholestatic jaundice**: Rare

### Fluphenazine

**Formulations**:
- Oral, IM decanoate (long-acting)

**Decanoate Injection**:
- Duration: 2-4 weeks
- Improves adherence in chronic schizophrenia
- Slow release from depot

**Adverse Effects**: Similar to haloperidol (high-potency)

---

## Atypical Antipsychotics

### Risperidone

**Receptor Profile**: D2 and 5-HT2A antagonist (ratio favors 5-HT2A)

**Pharmacokinetics**:
- Oral, IM long-acting (Risperdal Consta - 2 weeks)
- Hepatic metabolism (CYP2D6) → active metabolite (9-hydroxyrisperidone)
- Half-life: 3-20 hours (oral)

**Clinical Uses**:
1. **Schizophrenia**
2. **Bipolar mania**
3. **Irritability in autism** (FDA-approved in children)
4. **Adjunct in major depression**

**Adverse Effects**:
- **EPS**: Dose-dependent (high doses → ↑EPS like FGAs)
  - Low doses (<6 mg/day): Low EPS
  - Higher doses: ↑EPS
- **Hyperprolactinemia**: Most common among SGAs
- **Weight gain**: Moderate
- **Sedation**: Moderate
- **Orthostatic hypotension**: Especially initial dosing (α1)
- **Sexual dysfunction**
- **QTc prolongation**: Minimal

**Dosing**: 1-6 mg/day (higher doses lose atypical advantages)

### Olanzapine

**Receptor Profile**: D2, 5-HT2A, H1, M1, 5-HT2C antagonist

**Pharmacokinetics**:
- Oral (tablet, ODT), IM short-acting, IM long-acting (Zyprexa Relprevv - monthly)
- Hepatic metabolism (CYP1A2)
- Half-life: 21-54 hours

**Clinical Uses**:
1. **Schizophrenia** (highly effective)
2. **Bipolar disorder** (mania, maintenance)
3. **Acute agitation** (IM)
4. **Chemotherapy-induced nausea** (off-label)
5. **Treatment-resistant depression** (with fluoxetine = Symbyax)

**Adverse Effects**:

**Metabolic Syndrome** - Highest risk among SGAs:
- **Weight gain**: Significant (average 5-10 kg)
- **Hyperglycemia**: ↑risk of diabetes
- **Dyslipidemia**: ↑triglycerides, ↑cholesterol
- Mechanism: H1, 5-HT2C blockade → ↑appetite

**Monitoring Required**:
- Baseline: Weight, BMI, fasting glucose, lipid panel
- Regular: Monthly weight, quarterly metabolic labs

**Other Effects**:
- **Sedation**: High (H1)
- **Anticholinergic**: Moderate (constipation, dry mouth)
- **EPS**: Very low
- **Prolactin elevation**: Minimal
- **Orthostatic hypotension**: Moderate

**Efficacy**: One of the most effective antipsychotics for positive symptoms

**Dosing**: 5-20 mg/day

### Quetiapine

**Receptor Profile**: D2 (low affinity), 5-HT2A, H1, α1 antagonist

**Pharmacokinetics**:
- Oral (IR, XR)
- Hepatic metabolism (CYP3A4)
- Half-life: 6 hours (IR), 7 hours (XR active metabolite)

**Clinical Uses**:
1. **Schizophrenia**
2. **Bipolar disorder** (mania, depression, maintenance)
3. **Major depressive disorder** (adjunct - XR formulation)
4. **Insomnia** (off-label, low doses)

**Unique Features**:
- **Low D2 affinity** → very low EPS risk
- Effective for **bipolar depression** (FDA-approved monotherapy)
- Sedating (useful for agitation, insomnia)

**Adverse Effects**:
- **Sedation**: Very high (H1) - dose at bedtime
- **Weight gain**: Moderate to high
- **Metabolic effects**: Moderate (diabetes, dyslipidemia)
- **Orthostatic hypotension**: High (α1)
- **Anticholinergic**: Moderate
- **EPS**: Minimal
- **Prolactin**: Minimal
- **Cataracts**: Animal studies (annual eye exams recommended)

**Dosing**:
- Schizophrenia: 150-750 mg/day
- Bipolar depression: 300 mg/day
- Insomnia (off-label): 25-100 mg qhs

### Aripiprazole

**Receptor Profile**: D2 **partial agonist**, 5-HT2A antagonist, 5-HT1A partial agonist

**Mechanism**: Dopamine system stabilizer
- When dopamine high (psychosis): Acts as antagonist
- When dopamine low (negative symptoms): Acts as agonist
- Prevents excessive dopamine blockade

**Pharmacokinetics**:
- Oral, IM short-acting, IM long-acting (Abilify Maintena - monthly, Aristada - monthly/6 weeks)
- Hepatic metabolism (CYP2D6, CYP3A4)
- Half-life: 75 hours (extensive)
- Active metabolite (dehydroaripiprazole)

**Clinical Uses**:
1. **Schizophrenia**
2. **Bipolar disorder** (mania, maintenance)
3. **Major depression** (adjunct)
4. **Irritability in autism**
5. **Tourette syndrome**

**Adverse Effects** - Favorable profile:

**Lowest Metabolic Risk**:
- **Weight gain**: Minimal to none
- **Diabetes risk**: Minimal
- **Lipid effects**: Minimal

**Lowest EPS Risk**:
- Akathisia: Most common (dose-dependent, 10-25%)
- Dystonia/parkinsonism: Rare

**No Prolactin Elevation**: May even decrease prolactin

**Other Effects**:
- **Akathisia**: Most troublesome side effect
- **Insomnia**: Common (activating)
- **Headache**
- **Nausea**
- **Agitation**

**Advantages**:
- Weight-neutral
- Low metabolic risk
- Can be given once daily
- Good adherence

**Dosing**: 10-30 mg/day (typical: 10-15 mg)

### Ziprasidone

**Receptor Profile**: D2, 5-HT2A, 5-HT1A, α1, 5-HT/NE reuptake inhibitor

**Pharmacokinetics**:
- Oral (with food - doubles absorption), IM short-acting
- Hepatic metabolism
- Half-life: 7 hours (BID dosing)

**Clinical Uses**:
1. **Schizophrenia**
2. **Bipolar mania**
3. **Acute agitation** (IM)

**Adverse Effects**:
- **Weight gain**: Minimal (favorable)
- **Metabolic effects**: Minimal
- **EPS**: Low
- **QTc prolongation**: Highest among SGAs
  - Contraindicated: QT >500 ms, recent MI, heart failure
  - Requires baseline ECG
- **Sedation**: Moderate
- **Orthostatic hypotension**: Moderate

**Advantages**: Weight-neutral, low metabolic risk

**Disadvantages**: BID dosing, QTc prolongation, must take with food

**Dosing**: 40-160 mg/day (divided BID)

### Paliperidone

**Relationship**: Active metabolite of risperidone (9-hydroxyrisperidone)

**Pharmacokinetics**:
- Oral extended-release, IM long-acting (Invega Sustenna - monthly, Trinza - 3 months)
- **No hepatic metabolism** (renally excreted unchanged)
- Half-life: 23 hours

**Advantages**:
- No CYP interactions
- Once-daily oral dosing
- Long-acting injection options

**Adverse Effects**: Similar to risperidone
- EPS, hyperprolactinemia, weight gain, QTc prolongation

**Dosing**: 3-12 mg/day (oral)

### Lurasidone

**Receptor Profile**: D2, 5-HT2A, 5-HT7 antagonist, 5-HT1A partial agonist

**Pharmacokinetics**:
- Oral (with food - ≥350 calories)
- Hepatic metabolism (CYP3A4)
- Half-life: 18 hours

**Clinical Uses**:
1. **Schizophrenia**
2. **Bipolar depression** (monotherapy or with lithium/valproate)

**Unique Feature**: FDA-approved for **bipolar depression**

**Adverse Effects**:
- **Weight gain**: Minimal
- **Metabolic effects**: Low
- **EPS**: Moderate (dose-dependent)
- **Akathisia**: Common
- **Sedation**: Low
- **Nausea**: Common

**Advantages**: Weight-neutral, effective for bipolar depression

**Dosing**: 20-120 mg/day (with food)

### Clozapine

**Receptor Profile**: D4 > D2, 5-HT2A, M1, H1, α1 (multiple receptors, weak D2 affinity)

**Unique Status**:
- **Most effective antipsychotic** for treatment-resistant schizophrenia
- **Only FDA-approved** for treatment-resistant schizophrenia
- Reduces suicidality in schizophrenia
- Last-line due to serious adverse effects

**Pharmacokinetics**:
- Oral (tablet, ODT)
- Hepatic metabolism (CYP1A2, CYP3A4)
- Half-life: 12 hours

**Clinical Uses**:
1. **Treatment-resistant schizophrenia** (failed ≥2 antipsychotics)
2. **Reduction of suicidal behavior** in schizophrenia/schizoaffective disorder
3. **Psychosis in Parkinson's disease** (low EPS)

**Efficacy**:
- 30-50% response in treatment-resistant patients
- Superior for negative symptoms
- Reduces aggression, hostility

**Adverse Effects** - Serious:

1. **Agranulocytosis** (1-2%):
   - Life-threatening
   - Risk highest in first 6 months
   - **Mandatory monitoring**: Clozapine REMS program
     - Weekly CBC for 6 months
     - Biweekly for 6 months
     - Monthly thereafter
   - **ANC <1500**: Hold clozapine, daily CBC
   - **ANC <1000**: Discontinue permanently

2. **Seizures** (5% at doses >600 mg/day):
   - Dose-dependent
   - Prophylactic valproate if high doses

3. **Myocarditis/Cardiomyopathy**:
   - Highest risk in first month
   - Monitor for chest pain, dyspnea, tachycardia

4. **Metabolic Syndrome** - Highest risk:
   - **Weight gain**: Severe (average 10-15 kg)
   - **Diabetes**: High risk
   - **Dyslipidemia**: High risk
   - Intensive metabolic monitoring required

5. **Hypersalivation** (sialorrhea):
   - Especially nighttime
   - May require anticholinergics

6. **Constipation**:
   - Can progress to ileus (rare but serious)
   - Aggressive bowel regimen

7. **Orthostatic Hypotension**:
   - Especially initial titration
   - Slow titration required

8. **Sedation**: Severe

**Monitoring Requirements**:
- **ANC**: Per REMS schedule
- **Metabolic**: Baseline and regular (weight, glucose, lipids)
- **Cardiac**: Baseline ECG, troponin if symptoms
- **Clinical**: Weekly visits initially

**Advantages**:
- Most effective for refractory psychosis
- Lowest EPS (can use in Parkinson's)
- Reduces suicidality
- Reduces aggression

**Dosing**:
- Start: 12.5 mg qd or BID
- Titrate slowly to 300-450 mg/day (divided doses)
- Max: 900 mg/day

**Drug Interactions**:
- Smoking (induces CYP1A2) → ↓levels
- Fluvoxamine (inhibits CYP1A2) → ↑levels
- Benzodiazepines → ↑sedation, respiratory depression risk

---

## Comparison: Typical vs. Atypical

| Feature | Typical (FGA) | Atypical (SGA) |
|---------|---------------|----------------|
| **Mechanism** | D2 antagonism | D2 + 5-HT2A antagonism |
| **Positive symptoms** | Effective | Effective |
| **Negative symptoms** | Less effective | More effective |
| **EPS risk** | High | Low (except risperidone high dose) |
| **Tardive dyskinesia** | Higher risk | Lower risk |
| **Prolactin** | ↑↑ | Variable (risperidone ↑, others ↓) |
| **Weight gain** | Low | High (especially olanzapine, clozapine) |
| **Metabolic syndrome** | Low | High (olanzapine, clozapine) |
| **Sedation** | Variable | Often higher |
| **Cost** | Lower (generic) | Higher |

---

## Adverse Effects Summary

### Extrapyramidal Symptoms (EPS)

**Mechanism**: D2 blockade in nigrostriatal pathway

**Types**:
1. **Acute dystonia** (hours-days): Muscle spasms
2. **Parkinsonism** (days-weeks): Rigidity, tremor, bradykinesia
3. **Akathisia** (days-weeks): Motor restlessness
4. **Tardive dyskinesia** (months-years): Involuntary movements

**Risk Factors**:
- High-potency FGAs > low-potency FGAs > SGAs
- Young males (dystonia), elderly females (TD)
- Higher doses, longer duration

**Treatment**:
- Acute dystonia: Benztropine, diphenhydramine (IM/IV)
- Parkinsonism: Benztropine, amantadine, reduce dose
- Akathisia: Propranolol, benzodiazepines, reduce dose
- Tardive dyskinesia: Valbenazine, deutetrabenazine, switch to clozapine

### Neuroleptic Malignant Syndrome (NMS)

**Features**: Fever, rigidity, autonomic instability, altered mental status, ↑CK

**Risk Factors**: High-potency FGAs, rapid dose escalation, dehydration

**Treatment**:
- **Stop antipsychotic immediately**
- Supportive care (cooling, hydration)
- Dantrolene (muscle relaxant)
- Bromocriptine (dopamine agonist)
- ICU care

**Mortality**: 10-20% if untreated

### Metabolic Syndrome

**Components**: Weight gain, hyperglycemia, dyslipidemia, hypertension

**Risk Ranking** (highest to lowest):
1. Clozapine, olanzapine
2. Quetiapine, risperidone, paliperidone
3. Asenapine, iloperidone, lurasidone
4. Aripiprazole, ziprasidone, brexpiprazole (lowest)

**Monitoring**:
- Baseline: Weight, BMI, waist circumference, fasting glucose, HbA1c, lipid panel, BP
- Follow-up: Weight monthly, labs quarterly

**Management**:
- Lifestyle modification
- Switch to lower-risk agent
- Metformin (for weight/glucose)
- Treat dyslipidemia, hypertension

### Hyperprolactinemia

**Mechanism**: D2 blockade in tuberoinfundibular pathway → ↑prolactin

**Risk**: Risperidone, paliperidone > FGAs >> others

**Effects**:
- Galactorrhea, gynecomastia
- Amenorrhea, sexual dysfunction
- Osteoporosis (chronic)

**Management**: Switch to prolactin-sparing agent (aripiprazole, quetiapine)

### QTc Prolongation

**Risk**: Ziprasidone > thioridazine, haloperidol IV > others

**Monitoring**: Baseline ECG if risk factors

**Risk Factors**: Electrolyte abnormalities (K+, Mg2+), cardiac disease, other QT drugs

**Concern**: Torsades de pointes (rare)

---

## Special Populations

### Dementia-Related Psychosis

**Black Box Warning**: All antipsychotics ↑mortality in elderly with dementia-related psychosis
- ↑Stroke, infections, cardiovascular events
- **Not FDA-approved** for this indication

**Alternatives**: Non-pharmacologic approaches preferred

### Pregnancy

**Category C**: Most antipsychotics
- Risk-benefit assessment required
- **Haloperidol**: Most data, generally preferred if needed
- **SGAs**: Limited data

**Neonatal Effects**: Extrapyramidal symptoms, withdrawal

### Parkinson's Disease Psychosis

**Challenge**: D2 blockade worsens motor symptoms

**Preferred Agents**:
1. **Pimavanserin** (FDA-approved): 5-HT2A inverse agonist (no D2 blockade)
2. **Clozapine**: Lowest EPS risk among antipsychotics
3. **Quetiapine**: Low D2 affinity (less evidence)

**Avoid**: All other antipsychotics (worsen parkinsonism)

---

## Long-Acting Injectable Antipsychotics (LAIs)

**Indication**: Improve adherence, prevent relapse

**Advantages**:
- Eliminates non-adherence
- Lower relapse rates
- Predictable pharmacokinetics

**Available Formulations**:

**FGAs**:
- Haloperidol decanoate (monthly)
- Fluphenazine decanoate (2-4 weeks)

**SGAs**:
- Risperidone (Risperdal Consta - 2 weeks)
- Paliperidone (Invega Sustenna - monthly, Trinza - 3 months)
- Aripiprazole (Abilify Maintena, Aristada - monthly/6 weeks)
- Olanzapine (Zyprexa Relprevv - monthly)

**Disadvantages**:
- Painful injection
- Cannot rapidly discontinue
- PDSS risk (olanzapine LAI - post-injection delirium/sedation syndrome)

---

## Drug Interactions

**CYP Interactions**:
- **CYP1A2 substrates** (clozapine, olanzapine):
  - Inducers (smoking) → ↓levels
  - Inhibitors (fluvoxamine) → ↑levels
- **CYP2D6 substrates** (risperidone, aripiprazole, haloperidol):
  - Inhibitors (fluoxetine, paroxetine) → ↑levels
- **CYP3A4 substrates** (quetiapine, lurasidone):
  - Inducers (carbamazepine) → ↓levels
  - Inhibitors (ketoconazole) → ↑levels

**Pharmacodynamic**:
- **QT-prolonging drugs**: Additive risk
- **CNS depressants**: Additive sedation
- **Anticholinergics**: Additive effects
- **Antihypertensives**: Additive hypotension

**Specific**:
- **Clozapine + benzodiazepines**: Respiratory depression risk
- **Lithium + antipsychotics**: Neurotoxicity risk (rare)

---

## Treatment Guidelines

### Schizophrenia

**First Episode**:
- Start with SGA (lower EPS, better tolerability)
- Consider metabolic risk vs. EPS risk
- Trial 4-6 weeks at therapeutic dose

**Inadequate Response**:
- Try different SGA (different receptor profile)
- After 2-3 trials → consider **clozapine**

**Treatment-Resistant** (failed ≥2 adequate trials):
- **Clozapine** is gold standard

**Maintenance**:
- Continue at least 1-2 years after first episode
- Lifelong after multiple episodes
- LAI for adherence issues

### Acute Agitation

**IM Options**:
- Haloperidol + lorazepam + benztropine
- Olanzapine IM
- Ziprasidone IM
- Aripiprazole IM

**Avoid**: Olanzapine IM + benzodiazepine (within 1 hour - respiratory depression)

---

## Clinical Pearls

1. **All antipsychotics equally effective for positive symptoms** (except clozapine superior for refractory)
2. **SGAs better for negative symptoms** than FGAs
3. **Clozapine most effective but most toxic** - reserve for treatment-resistant
4. **Metabolic monitoring mandatory** for all SGAs
5. **Start low, go slow** in elderly and first episode
6. **Never use antipsychotics PRN long-term** - require regular dosing for efficacy
7. **TD risk increases with duration** - use lowest effective dose
8. **Akathisia most distressing** to patients - treat aggressively
9. **Hyperprolactinemia** - consider aripiprazole or quetiapine if problematic
10. **Smoking cessation** - may ↑clozapine/olanzapine levels (reduce dose)
11. **Aripiprazole best metabolic profile** but akathisia limiting
12. **Risperidone loses atypical advantages** at high doses (>6 mg)
13. **QTc monitoring** for ziprasidone, haloperidol IV, thioridazine
14. **Dementia psychosis** - non-pharmacologic first (Black Box Warning)

---

## Key Takeaways

1. **Mechanism**: FGAs (D2 antagonism), SGAs (D2 + 5-HT2A antagonism)
2. **Classification**: Typical (high/low potency) vs. Atypical
3. **High-potency FGAs** (haloperidol): ↑EPS, ↓sedation/anticholinergic
4. **Low-potency FGAs** (chlorpromazine): ↓EPS, ↑sedation/anticholinergic
5. **SGAs**: Lower EPS but higher metabolic risk
6. **EPS types**: Dystonia, parkinsonism, akathisia, tardive dyskinesia
7. **NMS**: Life-threatening emergency - stop drug immediately
8. **Metabolic syndrome**: Clozapine, olanzapine > quetiapine, risperidone > aripiprazole, ziprasidone
9. **Clozapine**: Most effective, requires REMS monitoring (agranulocytosis)
10. **Aripiprazole**: Partial agonist, lowest metabolic/EPS risk, akathisia common
11. **Hyperprolactinemia**: Risperidone > FGAs >> other SGAs
12. **Dementia psychosis**: Black Box Warning (↑mortality) - avoid

---

## References

1. Stahl's Essential Psychopharmacology, 5th Edition
2. Katzung's Basic & Clinical Pharmacology, 15th Edition
3. American Psychiatric Association Practice Guidelines for Schizophrenia
4. Leucht S, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013.
5. Clozapine REMS Program Guidelines
6. FDA Drug Safety Communications - Antipsychotics
7. Goodman & Gilman's Pharmacological Basis of Therapeutics, 14th Edition
